Exponent Inc stock (US30214U1025): Executives sell shares amid price drop

Exponent Inc executives Joseph Sala and Joseph Rakow sold over 5,000 shares on May 13, 2026, per SEC filings, as the stock fell around 4.6% to about $54-57.

Exponent Inc executives disclosed significant share sales in recent SEC Form 4 filings. On May 13, 2026, Group Vice President Joseph Sala sold 2,066 shares at $56.66 per share, according to Stock Titan as of May 14, 2026. Separately, Group Vice President Joseph Rakow sold 2,945 shares at an average of $54.6601 per share, per Stock Titan as of May 14, 2026. Shares traded around $54.56-$56.66 that day, with reports of a 4.6% decline.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exponent Inc
• Sector/industry: Engineering and scientific consulting
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: Failure analysis, litigation support
• Home exchange/listing venue: Nasdaq (EXPO)
• Trading currency: USD

Exponent Inc: core business model

Exponent Inc provides engineering and scientific consulting services to address complex technical challenges. The firm analyzes failures in products, infrastructure, and environments for clients including corporations, government agencies, and insurers. Services span biomechanics, materials science, and environmental health, often supporting litigation or regulatory matters. Headquartered in Menlo Park, California, Exponent operates globally with revenues primarily from US clients.

The company employs over 1,000 scientists and engineers, leveraging multidisciplinary expertise. Its model relies on billable hours from expert witnesses and investigative reports, with a focus on high-value, non-recurring projects. Exponent maintains a reputation for objective analysis in high-stakes cases, relevant to US investors tracking litigation support firms amid rising product liability claims.

Main revenue and product drivers for Exponent Inc

Revenue stems from four main practices: engineering, environmental sciences, biomedical, and management consulting. Engineering, the largest segment, covers mechanical failures and automotive crashes. Biomedical analyzes medical devices and pharmaceuticals. In Q4 2025 results published February 27, 2026, per the company's IR site, revenues reached $522 million for the year, up 4% from prior year.

Key drivers include demand for failure investigations post-accidents or recalls, plus regulatory compliance work. US market exposure is significant, with 85% of revenues domestic as of latest filings. Growth ties to industrial sectors like energy and consumer products, where safety standards drive consulting needs.

Industry trends and competitive position

The engineering consulting sector grows with complex regulations and litigation volumes. US product liability cases rose 10% in 2025 per court data, boosting demand for firms like Exponent. Competitors include FTI Consulting and Jensen Hughes, but Exponent differentiates via PhD-level expertise and Nasdaq listing (EXPO), appealing to US institutional investors.

Why Exponent Inc matters for US investors

Listed on Nasdaq, Exponent offers exposure to resilient consulting amid economic cycles. Its stable cash flow from recurring expert services contrasts volatile tech peers. With strong US revenue (over 80%), it benefits from domestic litigation trends and infrastructure spending under recent bills, making it relevant for diversified portfolios.

Conclusion

Recent insider sales by Exponent Inc executives highlight ongoing transaction activity, coinciding with a share price dip on May 13, 2026. The firm continues leveraging its niche in scientific consulting amid steady US demand. Investors monitor SEC filings for patterns, while core operations remain focused on high-expertise services. Market dynamics in litigation and regulation shape its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.